A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting
| Autor: | Danica Wasney, Vi Dao, Emily Rimmer, Scott Streilein, Leonard Minuk, Rami Kotb, Marc Geirnaert, Kristen Martin, Jacy Howarth, Chad Ricard |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Rapid infusion 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols Outpatients Prevalence medicine Humans Pharmacology (medical) Infusion reaction Infusions Intravenous Multiple myeloma Retrospective Studies business.industry Incidence (epidemiology) Antibodies Monoclonal Daratumumab Middle Aged medicine.disease 030220 oncology & carcinogenesis Female Multiple Myeloma business 030215 immunology |
| Zdroj: | Journal of Oncology Pharmacy Practice. 27:907-910 |
| ISSN: | 1477-092X 1078-1552 |
| Popis: | Background Daratumumab is used in the treatment of relapsed multiple myeloma. Daratumumab infusion-related reactions can occur with the highest incidence on the first infusion. Methods A retrospective review of all daratumumab infusions used as part of the DVd and DRd regimens for relapsed multiple myeloma was undertaken. The review of infusion-related reactions was conducted by reviewing the treatment room nursing note on the days that daratumumab was administered. If the patient experienced an infusion-related reaction, then the data captured included if the full dose was administered. Results Daratumumab infusion-related reactions occurred most frequently on the first dose. The rates of infusion-related reactions using a split dose approach for daratumumab administration were lower than that reported in clinical trials. All of the infusion-related reactions were managed with appropriate interventions in the outpatient setting. The adoption of rapid infusion daratumumab beginning with cycle 2 of DVd and DRd was well tolerated. Conclusions Our experience of daratumumab infusions using a split dose approach was associated with an infusion-related reaction rate in 28% of patients on cycle 1, day 1 of DVd and DRd regimens. All patients were able to complete full doses of daratumumab by utilizing split dose. The rates of daratumumab infusion-related reactions are highest on the first infusion. In addition, our adoption of rapid infusion daratumumab was safe. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|